Revenue 78% YoY but profit +5%—margin compression masks growth momentum

Revenue up 78% YoY driven by ARPOB+footfall; but PAT +5.4% shows bottom-line margin compression

NPM 7.6%, OPM 17.5%; India hospital EBITDA margin expanded but consolidated margin compressed by insurance+clinic+UK losses

Insurance losses spiked significantly; management acknowledged 'volatile' but no quantified path to profitability given

66,000 clinic consultations Q1, 30% YoY growth; clinic losses ₹15 Cr; referral value qualitative only

UK revenue up only 5% YoY; losses increased QoQ due to heat wave impact; regulatory delays 4-6 months; margin recovery timeline uncertain

Q1 saw significant insurance losses; Q4 prior call did not flag this risk; management now frames as temporary small-book volatility but no loss cap or timeline to profitability given.

Heat wave impact (lost operating days, HVAC failures) plus regulatory certification delays 4-6 months; YoY revenue only +5% despite 'substantial opportunity' thesis; margin recovery now uncertain.

40% EBITDA growth despite no bed additions; ARPOB + footfall combo working; robotics and high-end procedures gaining traction; India segment performance exceeded expectations.

30% YoY growth (66k consultations) and 2 new openings Q1; but ₹15 Cr loss acknowledged; management confident on referral and brand value but profitability path unclear.

₹3,000 Cr over 2 years reiterated; no new targets or cuts; forward guidance qualitative (margin expansion, no bed adds for 2-3 years) but no specific FY27 numbers offered.

High-end procedures, robotics, clinics (30% of OPD footfalls) driving brand and referrals; margin expansion from leverage; will pursue combination of volumes and realizations going forward; no specific guidance on mix.

Expansion will continue from leverage benefit (no bed additions for 2-3 years); but must balance reinvestment in clinics, integrated care, and customer pricing—not possible to project specific level.

Small book volatility; 'a few policies' caused spike; initiatives underway (AI claims review, in-housing, better risk selection, SME focus); loss ratio will moderate with scale over time; short-term volatility expected.

Not prepared to disclose numbers; insurance still small and volatile; working to win customers to own hospitals via service quality; group side numbers improving; retail side customers choose own hospitals.

Clinic footfalls (third of flagship hospital volume) drive referrals to complex/robotic procedures; clinics enable understanding of consumption patterns for underwriting; ability to intervene earlier and recommend surgery when appropriate; unique data advantage.

Short-term conflict but long-term self-check mechanism; if hospital does too much, insurance not sustainable; if too little, poor patient outcomes; abundant choice means customers leave if care denied; integrated model disciplines optimal care level.

Too early to measure ROCE (just acquired); no specific target disclosed; assets acquired at reasonable price with substantial opportunity to improve earnings without major capex; early days; will consider target disclosure in 4+ quarters.

Sourced from operating business performance in India and Cayman; to be deployed into committed projects over next 2 years (₹3,000 Cr capex, part own contribution, part borrowing).

OP consults grew ~30% YoY; 66,000 consultations this quarter across clinic network; very high % of clinic revenue from insurance members; opening 2 more clinics this quarter; integrated story playing out positively.

Evaluating all opportunities; current capex wave focused on established clusters where company is strong and has track record; Phase 2 (after Phase 1 progress) will consider newer geographies; not yet present in mentioned states.

100% renewal acceptance in July (unusual for new insurer); price increases to sustainable level accepted; expect similar result in Jan cycle; worst likely behind (rolling 2-3 q basis) barring abnormal large claims; sequentially improved Q1.

Q1 seasonally weaker; volume metrics (discharges, footfalls) showing healthy double-digit growth; USD60M annualized insurance book not small—should drive better growth next few quarters; early July/Aug looking positive.

Widespread UK heat wave (severe, affected critical infrastructure); HVAC/chillers failed, lost several operating days; catastrophic impact in low-margin business; year-on-year revenue +5% (would be higher without heat wave); integration progressing well, separations complete, on transformation plan; regulatory timelines slightly longer than expected but opportunity scope still close to pre-acquisition estimate.

Q4 reclass: Cayman professional fees moved from employee cost line to professional fees line, making Q4 negative; Q1 normal accounting; actual cost flat between quarters—accounting reclassification, not actual cost increase.

UK medical software classified as software as medical device (depending on use), requiring certification timeline; regulatory/data privacy processes pre-acquisition, but details not known; adds ~4-6 months to initial timeline estimate; one-time effort; advantage is few competitors have UK medical device classification at this scale.

95:5 at acquisition; better now but not enough to disclose; expected to take 4-5 years to reach 70% (peer level); early results promising; doctor engagement, insurance relationships, hospital location/structure all need redone; worthwhile because private payer realization significantly higher; journey underway.

Q1 delivered 78% YoY; no specific FY27 target; management emphasizes combination of volumes and realizations

India segment margins expanding; but consolidated margins compressed by insurance/clinic/UK losses; timing of margin inflection unclear

NHIC (India) losses spike indicates volatility; Cayman repricing benefits in Q2+; timeline to profitability not quantified

Southwest Bangalore 100 beds by end Q2; several projects within acceptable 6-month delay window; asset-light partner model delays resolving

NHIC (India) losses spike Q1; Cayman Insurance 3x AUM YoY but still small; both showing volatility. Management frames as temporary but no loss cap, break-even target, or max acceptable cumulative loss disclosed.

UK revenue only +5% YoY; losses increased sequentially Q1. Heat wave caused HVAC failures and lost operating days—catastrophic in low-margin business. Regulatory certification delays 4-6 months. NHS dependency 95% (peer ~70%); payer-mix shift to private (5% vs 95%) still very early. Integration still ongoing; no specific ROCE target or profitability timeline given.

Clinic losses ₹15 Cr Q1 despite 30% YoY growth (66k consultations); now opening 2+ new clinics per quarter. Management frames as strategic brand and referral driver (30% of hospital OPD), but cash burn material and profitability model not detailed.

Revenue +78% YoY but PAT +5.4%—dramatic gap signals bottom-line margin compression. India hospital EBITDA margin expanding, but consolidated result diluted by insurance losses, clinic losses (₹15 Cr), UK acquisition costs (capex, integration, heat wave), and new business initiatives. Risk: margin expansion thesis unravels if new businesses don't monetize quickly.

Several projects postponed from FY28 to FY29/FY30; asset-light partner model delays due to licensing issues (resolving in ~1 month per management). Southwest Bangalore 100 beds expected end Q2 (on track). Most projects within acceptable 6-month delay window. ₹3,000 Cr capex over 2 years remains on track.